Eleonora Restuccia

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Martine Piccart, Marion Procter, Debora Fumagalli et al. · Journal of Clinical Oncology · 2021 · 359 citations · Full text

Medicine, Oncology, Pharmacology +17

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Antoinette R. Tan, Seock‐Ah Im, André Mattar et al. · The Lancet Oncology · 2020 · 165 citations

Medicine, Oncology, Pharmacology +16

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

Charles E. Geyer, M. Untch, Chiun‐Sheng Huang et al. · New England Journal of Medicine · 2025 · 115 citations · Full text

Medicine, Oncology, Pharmacology +14

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

Jens Huober, Carlos H. Barrios, Naoki Niikura et al. · Journal of Clinical Oncology · 2022 · 114 citations · Full text

Medicine, Oncology, Pharmacology +17